Literature DB >> 1911211

Tumour progression and the nature of cancer.

W H Clark1.   

Abstract

The nature of neoplasia and its sometime end result, cancer, has been studied by exposition and explanation of the sequential lesions of tumour progression. Neoplastic lesions were divided into four classes on the basis of growth characteristics and whether lesional growth is confined to one or more tissue compartments. Class IA, the initial lesion, an orderly, probably clonal growth, usually differentiates and disappears. Class IB: Failure to differentiate accompanied by disorderly growth. Class IC: Randomly dispersed atypical cells, constituting a precursor state. Class II, intermediate lesions, apparently arising from the atypical cells, show temporally unrestricted growth within the tissue compartment of origin. Class III lesions, primary invasive cancers, show temporally unrestricted growth in two or more tissue compartments and metastasise along different paths, a property associated with extracellular matrix interaction. The metastatic pathways may result from different subsets of cells in the primary cancer. Class IV lesions are the metastases. It was concluded that, all neoplasms develop in the same way, have the same general behavioural characteristics, and, when malignant, all interact with the extracellular matrix of the primary and the secondary sites. The origins and development of cancer are considered to be pluralistic and not due to a discrete change in a cell, whose progeny, as a result of that discrete change, carries all of the information required to explain the almost limitless events of a neoplastic system.

Entities:  

Mesh:

Year:  1991        PMID: 1911211      PMCID: PMC1977704          DOI: 10.1038/bjc.1991.375

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

Review 1.  Biology of melanoma invasion and metastasis.

Authors:  L A Liotta; R Guirguis; M Stracke
Journal:  Pigment Cell Res       Date:  1987

2.  Melanosomal alterations in dysplastic melanocytic nevi. A quantitative, ultrastructural investigation.

Authors:  A R Rhodes; Y Seki; T B Fitzpatrick; R S Stern
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

3.  Melanocytic atypia in dysplastic nevi. Immunohistochemical and cytophotometrical analysis.

Authors:  W Bergman; D J Ruiter; E Scheffer; W A van Vloten
Journal:  Cancer       Date:  1988-04-15       Impact factor: 6.860

4.  Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus).

Authors:  K J Smith; T L Barrett; H G Skelton; G P Lupton; J H Graham
Journal:  Am J Surg Pathol       Date:  1989-11       Impact factor: 6.394

5.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

6.  Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.

Authors:  D E Elder; U Rodeck; J Thurin; F Cardillo; W H Clark; R Stewart; M Herlyn
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

7.  Human nevocellular nevus cells are surrounded by basement membrane components. Immunohistologic studies of human nevus cells and melanocytes in vivo and in vitro.

Authors:  M Yaar; D T Woodley; B A Gilchrest
Journal:  Lab Invest       Date:  1988-02       Impact factor: 5.662

8.  Monoclonal antibody (AFH1) immunoreactive on morphologically abnormal basal melanocytes within dysplastic nevi, nevocellular nevus nests, and melanoma.

Authors:  P J Aronson; K Ito; T Fukaya; K Hashimoto; A H Mehregan
Journal:  J Invest Dermatol       Date:  1988-04       Impact factor: 8.551

9.  Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia.

Authors:  A H Parmiter; G Balaban; W H Clark; P C Nowell
Journal:  Cancer Genet Cytogenet       Date:  1988-02

10.  The flow cytometry of melanocytic skin lesions.

Authors:  J A Newton; R S Camplejohn; D H McGibbon
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  65 in total

1.  E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors.

Authors:  M Y Hsu; F E Meier; M Nesbit; J Y Hsu; P Van Belle; D E Elder; M Herlyn
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  High rate of diversification and reversal among subclones of neoplastically transformed NIH 3T3 clones.

Authors:  A L Rubin; A Sneade-Koenig; H Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 3.  Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

Authors:  Paul B Fisher; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Pankaj Gupta; Moira Sauane; Zao-zhong Su; Steven Grant; Paul Dent; David T Curiel; Neil Senzer; John Nemunaitis
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-23       Impact factor: 4.219

4.  Engineering Controlled Peritumoral Inflammation to Constrain Brain Tumor Growth.

Authors:  Tarun Saxena; Johnathan G Lyon; S Balakrishna Pai; Daniel Pare; Jessica Amero; Lohitash Karumbaiah; Sheridan L Carroll; Eric Gaupp; Ravi V Bellamkonda
Journal:  Adv Healthc Mater       Date:  2018-12-11       Impact factor: 9.933

5.  msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation.

Authors:  T Shioda; M H Fenner; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

6.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

Authors:  M Y Hsu; D T Shih; F E Meier; P Van Belle; J Y Hsu; D E Elder; C A Buck; M Herlyn
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

7.  A novel role of myosin VI in human prostate cancer.

Authors:  Thomas A Dunn; Shenglin Chen; Dennis A Faith; Jessica L Hicks; Elizabeth A Platz; Yidong Chen; Charles M Ewing; Jurga Sauvageot; William B Isaacs; Angelo M De Marzo; Jun Luo
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

Review 9.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 10.  Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis.

Authors:  J R MacDougall; L M Matrisian
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.